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[Clinical Information]
Patient initials or identiﬁer number:
JS, 54 years old
Relevant clinical history and physical exam:
Patient was hospitalised for 25 days after suffer from hemorrhagic stroke that un-
derwent decompression craniotomy immediately. He had hemiplegia and partial
aphasia. he was training by the physiotherapist, but still in bed not mobilise well.
He had not any anticoagulant to prevent tromboembolism until he suddenly had short
of breath and decreased BP and peripheral saturation.
Relevant test results prior to catheterization:
ECG: Sinus Tachycardia, T inverted @ III, S deeper @ I,
Echocardiogram: Good LVEF (66%)
Trivial AR
Severe TR, TVG 44mmHg
RV dilatation
Laboratory: D Dimer 5.9 ml/L
Relevant catheterization ﬁndings:
Pulmonary Artery Angiography Shown: Massive Right Pulmonary Artery
Thromboembolism
[Interventional Management]
Procedural step:
1. Puncture right femoral vein then inserted 7Fr sheath
2. PA angiography was performed with 6Fr pigtail catheter in main pulmonary
artery
3. Massive right pulmonary thromboembolism was conﬁrmed
4. Thromboembolectomy was planned.
5. Temporary pacemaker (St. Jude lead 6Fr) was inserted to right ventricle apex
from left femoral vein.
6. Xpeedior trombectomy catheter set was inserted to right pulmonary artery
guided with Merit Laureate 260cm 0,035 inch guide wire.
7. Suction was performed with angiojet(R) ultra thrombectomy system.
8. Heparin 5000 i.u intravenously was given during procedure
9. Post procedural evaluation was performed with pigtail catheter 6F.
10. After thrombectomy patients was receive enoxaparin 0.6ml sc twice daily
continued with Rivaroxaban 15mg twice daily for 3 weeks.
11. After 3 weeks rivaroxaban dose was decreased to 20mg once daily.
12. 1 month after thrombectomy Pulmonary artery CT-scan shown minimal re-
sidual thrombus in right pulmonary artery. The D-dimer was below 0.3ml/L
13. Patients was underwent second operation to close the craniotomy and the rivar-
oxaban was suspend for 5 days, 1 days before surgery and 4 days after surgery.
14. 6 months later PA MSCT shown no thrombus anymore in both pulmonary
artery and all the branchs.S88 JACC Vol 63/12/Suppl S j April 22–25, 2Case Summary:
Successful thrombolectomy with Angiojet in a patient with hemorrhagic stroke post
craniotomy continued with Rivarixaban. 1 month after thrombolectomy rivaroxaban was
discontinued for 1 week due to patient underwent second surgery to close the craniotomy.
6 months after thrombolectomy (17 December 2013) PA MSCT shown clear in both
pulmonary artery, no residual thrombus.
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[Clinical Information]
Patient initials or identiﬁer number:
M.T and H.Y
Relevant clinical history and physical exam:
During primary PCI of ACS patients, we often face to coronary thrombi which cannot
be retrieved by aspiration catheter. I would like to introduce two RCA ACS cases with
large amount coronary thrombi.
[Case1] A 71-year old man was admitted with chest pain started four hours ago. His
risk factors were dyslipidemia, and former smoking. Physical examination revealed no
signiﬁcant ﬁndings.
[Case2] A 55-year old man was admitted with chest pain started 11 hours ago. His risk
factors were hypertension, dyslipidemia, and current smoking. Physical examination
revealed no signiﬁcant ﬁndings.
Relevant test results prior to catheterization:
[Case1] Chest X-ray was unremarkable. ECG showed ST elevation at V1 to 4. Mildly
decreased motion at inferior wall was detected by echocardiogram. Elevation of
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